Skip to Content

Idelalisib

In the US, Idelalisib (idelalisib systemic) is a member of the drug class multikinase inhibitors and is used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoma and Non-Hodgkin's Lymphoma.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XX47

CAS registry number (Chemical Abstracts Service)

0870281-82-6

Chemical Formula

C22-H18-F-N7-O

Molecular Weight

415

Therapeutic Category

Antineoplastic agent

Chemical Name

5-fluoro-3-phenyl-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}quinazolin-4(3H)-one (WHO)

Foreign Names

  • Idelalisibum (Latin)
  • Idelalisib (German)
  • Idélalisib (French)
  • Idelalisib (Spanish)

Generic Names

  • Idelalisib (OS: USAN, JAN)
  • CAL-101 (IS)
  • GS-1101 (IS)
  • UNII-YG57I8T5M0 (IS)

Brand Names

  • Zydelig
    Gilead, Canada; Gilead, Switzerland; Gilead, Germany; Gilead, Finland; Gilead, France; Gilead, Ireland; Gilead, Poland; Gilead, Sweden; Gilead, Slovakia; Gilead, United States; Gilead Sciences, United Kingdom

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide